Literature DB >> 9422508

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.

M Ricote1, A C Li, T M Willson, C J Kelly, C K Glass.   

Abstract

The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors that is predominantly expressed in adipose tissue, adrenal gland and spleen. PPAR-gamma has been demonstrated to regulate adipocyte differentiation and glucose homeostasis in response to several structurally distinct compounds, including thiazolidinediones and fibrates. Naturally occurring compounds such as fatty acids and the prostaglandin D2 metabolite 15-deoxy-delta prostaglandin J2 (15d-PGJ2) bind to PPAR-gamma and stimulate transcription of target genes. Prostaglandin D2 metabolites have not yet been identified in adipose tissue, but are major products of arachidonic-acid metabolism in macrophages, raising the possibility that they might serve as endogenous PPAR-gamma ligands in this cell type. Here we show that PPAR-gamma is markedly upregulated in activated macrophages and inhibits the expression of the inducible nitric oxide synthase, gelatinase B and scavenger receptor A genes in response to 15d-PGJ2 and synthetic PPAR-gamma ligands. PPAR-gamma inhibits gene expression in part by antagonizing the activities of the transcription factors AP-1, STAT and NF-kappaB. These observations suggest that PPAR-gamma and locally produced prostaglandin D2 metabolites are involved in the regulation of inflammatory responses, and raise the possibility that synthetic PPAR-gamma ligands may be of therapeutic value in human diseases such as atherosclerosis and rheumatoid arthritis in which activated macrophages exert pathogenic effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9422508     DOI: 10.1038/34178

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  957 in total

1.  Genetics and molecular biology: a role for adipocyte lipid-binding protein in atherosclerosis.

Authors:  Jheem D Medh
Journal:  Curr Opin Lipidol       Date:  2002-02       Impact factor: 4.776

Review 2.  Sepsis-induced immunosuppression: from bad to worse.

Authors:  R C Reddy; G H Chen; P K Tekchandani; T J Standiford
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 3.  Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes.

Authors:  S L Tilley; T M Coffman; B H Koller
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 4.  Vascular inflammation as a therapeutic target for prevention of cardiovascular disease.

Authors:  Luther T Clark
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

5.  Prostaglandin and PPAR control of immune cell function.

Authors:  Dino Rotondo; Jillian Davidson
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

Review 6.  Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease.

Authors:  J S Sidhu; J C Kaski
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 7.  Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer.

Authors:  Y Yamamoto; R B Gaynor
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

8.  Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: ending the heartache.

Authors:  E D Rosen; B M Spiegelman
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

9.  Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo.

Authors:  M T Heneka; T Klockgether; D L Feinstein
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

10.  Influence of peroxisome proliferator-activated receptor (PPAR)gamma Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese.

Authors:  Tomomitsu Tahara; Tomiyasu Arisawa; Tomoyuki Shibata; Masakatsu Nakamura; Fangyu Wang; Naoko Maruyama; Yoshio Kamiya; Masahiko Nakamura; Hiroshi Fujita; Mitsuo Nagasaka; Masami Iwata; Kazuya Takahama; Makoto Watanabe; Ichiro Hirata; Hiroshi Nakano
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.